Chapter 84: Other Gastrointestinal Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when we think about the human gastrointestinal tract, I feel like the instinct is just to picture this purely mechanical plumbing system.

Like, we imagine a series of pipes and valves just moving material from point A to point B.

Right, yeah, it's a super common oversimplification.

I mean, we tend to reduce digestion to just sheer physics and, you know, peristalsis, totally ignoring the sophisticated communication network that actually runs the whole thing.

Welcome to the Deep Dive.

Today, we are tailoring our focus entirely for you, the nursing student listening right now, who is probably deep in preparation for a major pharmacology exam.

Absolutely.

We are taking your source material, specifically Chapter 84 of LANDS Pharmacology for Nursing Care, which covers all those other gastrointestinal drugs, and we're translating it.

Yeah, we're moving away from that dry, intimidating list of drug names and side effects.

Our mission today is to dive into the actual neurochemical landscape of the gut.

Because honestly, when you understand the underlying electrical grid, you don't have to Well, they make logical sense.

Exactly.

So to understand that grid, we actually have to start the top, right?

Like, in the brain.

Because if we're looking at anti -emetics drugs that stop nausea and vomiting, we first have to understand the emetic response itself.

Right.

Vomiting is definitely not just a simple stomach spasm.

It is this highly coordinated reflex controlled by the vomiting center, which is a specific cluster of neurons located in the medulla oblongata.

And vomiting center doesn't just act on its own, does it?

I mean, it has to receive a signal to fire.

The text mentions two pathways, direct and indirect.

Yes.

So direct triggers are those immediate sensory inputs,

you know, fear, nauseous odors, upsetting sites,

or vestibular signals from the inner ear during motion sickness.

Those go straight to the vomiting center.

Okay, but the indirect pathway is where our major pharmacology comes into play.

And that involves the tumor receptor trigger zone, or the CTZ.

Exactly.

Think of the CTZ as a highly sensitive chemical smoke detector.

It just sits near the medulla, constantly sampling the blood and the cerebrospinal fluid for toxins.

And it also receives distress signals sent up from the stomach and small intestine via the vagus nerve, right?

Yes, precisely.

So if the CTZ is the smoke detector, then compounds like powerful anti -cancer drugs or opioids circulating in the blood are the smoke.

Got it.

The CTZ detects them, alarms the vomiting center, and then the vomiting center basically orchestrates the diaphragm, stomach, and abdominal muscles to violently expel everything.

Which means logically to stop the vomiting, we need to disable the alarm system.

And that brings us to our most widely used class of antiemetics, which are the serotonin receptor antagonists.

Okay, the prototype you will see constantly in clinical practice here is Ondansetron, brand name Zofran.

Right.

So using that smoke detector analogy, if serotonin is the chemical messenger trying to trigger the alarm, Ondansetron works by taking the batteries out of the system.

It specifically blocks type 3 serotonin receptors, right?

The 5 -HT3 receptors.

And those are located both in the CTZ and on those vagal nerve endings in the upper GI tract.

Exactly.

And because it blocks those specific receptors so effectively, it is the absolute cornerstone drug for chemotherapy -induced nausea and vomiting, or CINV.

It's also used for nausea related to radiation therapy, anesthesia, and even off -label for severe viral gastritis.

But as a nurse, you really have to monitor the systemic effects of blocking these receptors.

Yeah, you do.

Ondansetron carries a crucial safety alert regarding the heart's electrical system.

Right.

We are talking about QT interval so if I remember my cardiac physiology correctly, the QT interval represents the time it takes for the heart ventricles to repolarize or electrically reset before the next beat.

That is the exact mechanism.

Ondansetron delays that electrical resetting.

And if the heart muscle takes too long to repolarize, it creates this window of vulnerability.

And a premature electrical impulse can sneak in there and trigger torsades to points, right?

Which is a potentially lethal ventricular dysrhythmia.

Exactly.

So the nursing implication isn't just, you know, watch the heart monitor.

It means you have to actively verify the patient's electrolyte panels, specifically potassium and magnesium, because imbalances worsen that electrical delay.

Right.

And you have to cross -check their chart for other QT prolonging drugs or a history of heart failure.

Caution is absolutely mandated there.

Now, Ondansetron is excellent for acute nausea, but cancer patients often suffer from debilitating nausea days after their chemotherapy infusion.

Oh, right.

And by that point, serotonin blockers alone just aren't sufficient.

We have to target a completely different receptor pathway.

Which brings us to the substance P -neurocanon -1 antagonists, specifically aprepetent, brand name Emend.

The major advantage of aprepetent is its prolonged duration of action, right?

By blocking substance P receptors in the brain, it prevents that delayed CINV.

It does.

But reading through the drug interactions, you'll see this drug is incredibly complex because of how with the cytochrome P450 enzyme system.

Yeah, it's a phenomenal example of pharmacokinetic interactions.

Aprepetent is metabolized by a liver enzyme called CYP3A4, but it also acts as an inhibitor of that exact same enzyme.

Right.

And when an enzyme is inhibited, its ability to break down molecules slows to a crawl.

Which means any other drug relying on CYP3A4 for clearance is going to get backed up in the bloodstream.

The plasma levels will just rise.

Exactly.

And since providers almost always prescribe glucocorticoids like dexamethasone alongside aprepetent for severe nausea, that steroid is going to accumulate.

Oh wow.

So if the nurse doesn't ensure the glucocorticoid dose is reduced, the patient could suffer steroid toxicity.

Yes, your clinical reasoning is spot on there.

But aprepetent's influence on the liver doesn't stop there.

While it inhibits one enzyme, it simultaneously induces another CYP2D6.

Wait, induction does the opposite, right?

It kicks the enzyme into overdrive, meaning it chews through drugs significantly faster.

You got it.

So for a patient taking warfarin, which is an anticoagulant metabolized by CYP2D6, their body is going to process and eliminate that warfarin way faster than normal.

So their blood levels will plummet, leaving them totally unprotected against blood clots.

And I assume the same goes for oral contraceptives.

Yeah, they'd be metabolized so quickly they might actually fail.

This is why nurses must monitor coagulation studies closely and counsel patients on alternative birth control.

That is so important.

Okay, moving to an older but still very common class, we have the dopamine antagonists.

The phenothiazines are the prototypes here, specifically promethazine or phenergan.

Right, and it blocks dopamine receptors in the CTZ.

But promethazine is everywhere, so why does the textbook hit us with such severe black box warnings?

I mean, first it says it is absolutely contraindicated in children under two years old because of fatal respiratory depression.

Yeah, that's a massive alert.

But the warning regarding intravenous administration is even more shocking.

The text says it can cause severe tissue necrosis and gangrene requiring amputation.

Yeah, how does a basic anti -nausea medication lead to an amputation?

It comes down to the chemical nature of the drug.

Promethazine is highly caustic to human tissue.

When it's injected properly into a large, freely flowing vein, the blood rapidly dilutes it and it travels safely to the brain.

But if that IV line extradicates, meaning the needle slips and the highly concentrated drug leaks out of the vein into the sluggish interstitial space of the surrounding tissue, it basically causes a massive chemical burn.

Exactly.

It destroys the cells on contact, so the tissue dies, necrosis sets in, and if it's severe enough, the limb literally can't be saved.

That is grim.

So the nursing implication is clear advocate for intramuscular administration whenever possible.

Subcutaneous injection is strictly prohibited.

Right.

And if an IV push is the absolute only option, it must be highly diluted, pushed very slowly through a large bore line, and you must immediately stop the infusion if the patient reports even the slightest burning sensation.

Definitely.

Oh, and a quick mention of dropper at all.

It's a beauty rope fan, but it also carries a serious risk for QT prolongation, so you need an ECG before giving it.

Good catch.

We should also briefly touch on the cannabinoids, specifically dronobinol, which is a synthetic derivative of THC.

Dronobinol is primarily a second -line therapy for CINV when primary drugs fail, right?

But it holds a unique indication.

It is approved to stimulate appetite in patients with AIDS, combating severe weight loss and cachexia.

Yes.

And what's interesting is its regulatory status.

It's a synthetic THC, but the DEA eventually moved it from Schedule 2 down to Schedule 3.

Right, because it's formulated as an oral capsule with a slow, delayed onset.

It just doesn't produce that immediate rush or high that comes from smoking marijuana.

The slower pharmacokinetic profile naturally lowers its street abuse potential.

Exactly.

Regardless of the schedule, though, nurses still need to monitor for classic psychoactive and cardiovascular side effects like tachycardia, hypotension, and dysphoria.

Okay, so with all these options, let's pull this into a clinical scenario.

How does a nurse know which one the provider will order?

Well, the textbook outlines clinical decision making beautifully in Table 84 .3.

In practice, a provider isn't going to rely on just one mechanism.

If a patient is receiving highly immunogenic chemo, they use a multi -pronged approach.

So like a three -drug regimen?

Yes.

You administer a prepidant to block substance P, dexamethasone to reduce inflammation and permeability,

and ondansetron to block serotonin.

You saturate the CTZ in the vomiting center from three different pharmacological angles to ensure no signal gets through.

Wow, that makes a lot of sense.

But you obviously can't use a heavy -duty chemo combo for something like morning sickness during pregnancy.

No, definitely not.

For pregnancy, the safest first -line therapy is a combination of doxylamine, which is an antihistamine, and vitamin B6 brand name declagis.

It is highly effective and lacks the fetal risks associated with those broader receptor antagonists.

And what if the trigger isn't chemical at all?

Like if the nausea is originating from the inner ear due to motion sickness, blocking serotonin in the gut or the CTZ isn't going to help because the signal is coming from the vestibular system.

That is exactly why we use a muscarinic antagonist like scopolamine for motion sickness.

It is usually applied as a transdermal patch behind the ear, directly suppressing the nerve traffic traveling from the vestibular apparatus to the vomiting center.

You can also use certain antihistamines like diamond hydrinate, but you have to remind the patient to watch for systemic anticholinergic side effects, right?

Dry mouth, blurred vision, urinary retention.

Always.

Okay, so we've seen how we can quiet the brain to stop nausea, but what happens when the chaos isn't in the brain, but lower down in the intestines?

Right.

When the physical gut goes into overdrive and things are moving too fast, how do we slow them down without causing systemic issues?

We need a totally different strategy to manage diarrhea.

And the primary pharmacological tool here is opioids.

I have to admit, giving someone a powerful narcotic to treat diarrhea sounds like an extreme overreaction.

Are we really giving people morphine for diarrhea?

It sounds like using a sledgehammer for a nail.

I know, it sounds super counterintuitive until you examine the distribution of opioid receptors in the human body.

We associate them with pain relief in the central nervous system, but the gastrointestinal tract is actually densely packed with mu -opioid receptors.

Oh, right.

So when an opioid binds to these receptors in the gut, it drastically decreases intestinal motility.

It slows down the peristalsis.

Exactly.

And because the material is moving so sluggishly through the intestines,

the colon has significantly more time to absorb water and electrolytes out of the waste.

The net effect is less fluid in the bowel lumen, meaning fewer, more formed stools.

But the challenge naturally is the risk of systemic euphoria and dependency.

True.

But this is where pharmacological engineering provides a brilliant solution with the drug dofenoxilate, brand name Lomotil.

It is an opioid, but the manufacturer formulates it with a subtherapeutic dose of atropine.

Wait, atropine is a potent anticholinergic.

Oh, I see the brilliant pharmacology here.

So if a patient takes the prescribed dose for diarrhea, the tiny bit of atropine does absolutely nothing.

Right.

But if a patient decides to swallow a handful of pills trying to access the opioid high,

that massive dose of atropine hits their system simultaneously.

Oh, wow.

So they get hit with intolerable anticholinergic toxicity, severe tachycardia, extreme dry mouth, blurred vision, and flushed skin.

The drug physically punishes abuse.

It's basically a chemical deterrent.

Now, contrast that with lopramide, brand name Imodium.

Lopramide is structurally related to meparidine, another opioid.

Okay, but wait, if lopramide is an opioid, why is it sitting on the shelf at the grocery store?

Shouldn't it be tightly controlled?

The difference lies in its ability to cross the blood -brain barrier.

Lopramide is a large, poorly absorbed molecule, and the tiny amount that does actually reach the brain is immediately pumped right back out by transport proteins.

Oh, so because it cannot effectively penetrate the central nervous system, it produces zero euphoria.

It stays localized in the gut, making it entirely safe for over -the -counter use.

Exactly.

But there is a massive caveat for any antidiarrheal, and it relates to infectious diarrhea.

If a patient comes in with diarrhea caused by a pathogen like salmonella or clostridioids difficile,

freezing the bowel with an opioid seems incredibly dangerous.

Right, you don't always want to stop the diarrhea.

That is a critical nursing consideration.

Diarrhea is the body's primary defense mechanism for expelling pathogens and their highly destructive toxins.

If you administer Lopramide during a severe infection, you halt peristalsis and trap that actively multiplying bacteria inside the colon.

The toxins will just degrade the bowel wall, potentially leading to toxic megacolon or systemic sepsis.

The rule is, let it out.

Support them with IV fluids, but don't trap the infection.

Now, if it's a mild case of traveler's diarrhea, usually from E.

coli, it resolves on its own.

But if symptoms are severe, providers will use a fluoroquinolone antibiotic like ciprofloxacin.

And for children or pregnant patients where fluoroquinolones are contraindicated, azithromycin is the standard.

Moving down the line from acute infections, we must discuss functional disorders, specifically irritable bowel syndrome or IBS.

IBS is fascinating because unlike an infection, there is no actual structural damage.

The Rome 5e criteria require crampy abdominal pain associated with defecation and changes in stool frequency or consistency present for at least 12 weeks in the past year.

Right.

It is a hyper -responsive, hypersensitive bowel reacting to stress, diet or hormonal shifts.

And we see two main types, IBSD for diarrhea and IBSC for constipation.

So for women with severe diarrhea, predominant IBS or IBSD, we use a drug called Allostron, brand name Lotrinix.

We do.

And here's the pharmacological puzzle for you.

Allostron works by blocking five HD3 receptors in the gut.

Wait, but we already established that Ondansetron blocks five HD3 receptors too.

So since Allostron does the exact same thing, why is it restricted to women with severe IBSD and why does it have such a strict risk management program?

It's all about the profound degree to which Allostron alters gut motility.

While Ondansetron acts more centrally and transiently to stop vomiting, Allostron binds really tightly to the receptors in the colon,

significantly prolonging transit time and vastly increasing fluid absorption.

Oh, I see the tight cause and effect here.

In severe IBSD, that is the therapeutic goal.

But if the drug overshoots, the consequences are catastrophic.

By overshooting, you mean it practically paralyzes the bowel.

Exactly.

It causes severe constipation that can lead to physical obstruction or impaction.

And the textbook warns heavily about ischemic colitis.

If the bowel completely stops moving and becomes distended, the physical pressure can compress the blood vessels supplying the

So the tissue is starved of oxygen.

Ischemic colitis is the literal death of the intestinal tissue due to lack of blood flow, which can lead to perforation and sepsis.

Deaths have actually occurred.

Yes, they have.

Therefore, the nursing implication is crucial.

Allostron is an absolute contraindication in anyone with a history of chronic constipation, diverticulitis, or Crohn's disease.

Got it.

Now for the constipation predominant form, IBSC, the approach is reversed.

Looking at table 84 .5, drugs like lubiprostone activate chloride channels in the intestinal lining to pull fluid into the lumen, softening the stool.

And linocleotide works similarly as a gonelate cyclase agonist, increasing intestinal fluid secretion and motility.

So let's contrast the functional hypersensitivity of IBS with the physical destructive pathology of inflammatory bowel disease, or IBD.

This is a vital distinction.

IBD encompasses Crohn's disease and ulcerative colitis.

This is an actual exaggerated autoimmune -driven inflammatory response.

The immune system is physically attacking the bowel wall.

Right.

Crohn's can be transmural, causing deep lesions to the entire thickness of the intestinal wall anywhere from the mouth to the anus.

Ulcerative colitis is typically mucosal, superficial inflammation confined strictly to the colon and rectum.

Because the pathophysiology is immune system misfiring, our pharmacological approach is entirely different.

The text outlines a stepwise therapy in table 84 .6, starting mild and escalating to heavy immune suppression.

Yes.

Step one involves the five amino salicylates, like sulfasalazine.

The mechanism here relies on the gut microbiome.

The drug is swallowed inactive and it travels down to the colon, where resident intestinal bacteria metabolize it into two distinct compounds,

5 -ASA and sulfapurity.

And the 5 -ASA is the therapeutic component.

It drastically reduces the local inflammation.

But the sulfapyridine, unfortunately, is a toxic byproduct.

Exactly.

And sulfapyridine is responsible for the severe adverse effects.

Beyond simple nausea or rash, it causes severe hematologic disorders, including

agranulocytosis, the destruction of white blood cells, and hemolytic anemia.

So the tight cause and effect means nurses must draw and monitor complete blood counts periodically to catch these marrow issues early.

Absolutely.

Now, if the five amino salicylates fail to control an acute flare -up, we escalate to step two.

Glucocorticoids like butanide or dexmethasone.

These are powerful systemic anti -inflammatories.

However, the safety alert here is non -negotiable.

They're only used to induce remission during a crisis, never for long -term maintenance.

Right.

Chronic steroid use will shut down the adrenal glands, leach calcium from the bones, causing severe osteoporosis, invite systemic infections,

and cause Cushing -Goyd syndrome.

You have to taper them off.

So what maintains the remission once the steroids are withdrawn?

That requires step three, immunosuppressants like azathioprine or mercaptopurine.

These alter the fundamental immune cascade, but their onset of action is incredibly slow, often taking up to six months to achieve full therapeutic effect.

Ah, so you have to bridge the patient.

You start the azathioprine, use the steroids to put out the immediate fire, and then slowly taper the steroids as the azathioprine finally kicks in.

Exactly.

And during that time, you monitor closely for signs of pancreatitis and neutropenia, which brings us to the final tier for severe refractory IBD, the immunomodulators or biologic agents.

The prototype here is infliximab.

These are the biologics you see commercials for all the time.

What's the catch with them?

Well, infliximab is a monoclonal antibody engineered to seek out and neutralize tumor necrosis factor or TNF.

If TNF is the commanding general ordering the white blood cells to attack the bowel, infliximab is the sniper that takes the general out.

It sounds remarkably effective, but by removing TNF, you are blinding a major sector of the patient's immune system, right?

Without that signaling pathway, the body loses its ability to fight off certain invaders.

Exactly.

Which explains the massive risk of opportunistic infections.

Patients on infliximab are at high risk for the reactivation of latent tuberculosis, severe fungal infections, and even an increased risk of developing lymphoma.

Wow.

So these are heavy duty medications that require meticulous nursing surveillance for any sign of fever or respiratory distress.

Very much so.

Okay.

To round out our exploration of the GI tract, we must address a handful of specific agents for GI motility, oral mucositis, and the accessory organs like the pancreas and gallbladder.

Let's start with metaclopramide, brand name Raglan.

Metaclopramide is a pro -kinetic agent.

It drastically increases the motility of the upper GI tract, forcing the stomach to empty faster, which is why it is heavily used for diabetic gastroparesis and severe GERD.

It also blocks dopamine and serotonin receptors in the CTZ, which has a really nice anti -matic effect.

But the safety alert attached to this drug is terrifying.

Yeah, prolonged high -dose therapy with metaclopramide can cause tardive dyskinesia.

Because it blocks dopamine in the central nervous system, it almost mimics the pathophysiology of Parkinson's disease.

Patients develop repetitive, involuntary movements of the face, tongue, arms, and legs.

And what makes it so dangerous is that even if you stop the drug, the tardic dyskinesia is often completely irreversible.

Older adults are incredibly vulnerable here.

The imperative is to use the lowest effective dose for the absolute shortest time possible.

Definitely.

Next, we have a highly specialized drug called Palifermin, brand name Keppavance.

It is used to decrease the incidence and duration of severe oral mucositis, those debilitating painful mouth ulcers that afflict patients undergoing intense chemotherapy.

It's a huge quality of life issue.

It really is.

This drug is a perfect study in cellular receptors.

Palifermin is a synthetic keratinocyte growth factor, or KGF.

When it binds to KGF receptors, it commands epithelial cells to rapidly divide and proliferate, healing the damaged tissue in the mouth.

But the text explicitly states it is only approved for patients with hematologic or blood -based cancers like leukemia.

Why is it only approved for blood cancers?

Think about where KGF receptors are located.

They exist exclusively on epithelial cells.

Blood cells do not have KGF receptors.

Therefore, giving Palifermin to a leukemia patient is

because the drug cannot physically interact with or stimulate the blood cancer cells.

Oh, that is such an aha moment.

Because if a patient has an epithelial tumor -like breast cancer or lung cancer, giving them a growth factor that stimulates epithelial cells could accidentally pour gasoline on the fire, you might accidentally stimulate the cancer cells to grow.

Exactly.

And regarding administration, nurses must strictly hold Palifermin for 24 hours before and after the actual chemotherapy infusion.

Right, because if the epithelial cells are actively rapidly dividing when the chemo hits, the mucositis will actually become significantly worse.

Bingo.

Finally, we end at the accessory organs.

For patients lacking pancreatic enzymes, such as those with cystic fibrosis, we administer pancreolipase.

The rapid -fire nursing teaching point here relates to the stomach's highly acidic environment.

Unprotected enzymes would be immediately destroyed by gastric acid.

Therefore, pancreolipase capsules are formulated as delayed release and taric -coated spheres.

Right, so if a patient crushes or chews the counsel, they destroy the coating.

The active enzymes will prematurely release in the mouth, actively digesting and ulcerating the oral mucosa, never crush or chew them.

And for gallstone management, we use ursodial.

This medication alters the composition of bile, reducing its cholesterol content to gradually dissolve radiolucent cholesterol gallstones.

The primary nursing education point here is managing patient expectations.

This is not a rapid intervention.

Complete dissolution requires months, sometimes years, of continuous therapy.

Wow.

And with that, we have traced the entire pharmacological map of Chapter 84.

We started from the CTZ in the deep nuclei of the medulla oblongata, blocking the chemical triggers of nausea.

We navigated down through the intestines, seeing how manipulating muopioid receptors can freeze motility, and how targeting cellular immune signals can halt the destruction of the bowel wall.

We've seen that every intervention, whether it's stopping vomiting, halting diarrhea, or soothing an inflamed bowel, carries a specific side effect cost that nurses must monitor.

It is the ultimate balancing act.

As you finalize your notes, I want to leave you with one overarching, provocative thought to ponder.

Notice the recurring cast of characters in this chapter.

Serotonin, dopamine, uopioids.

Yeah, they keep popping up.

We are culturally conditioned to view these strictly as brain chemicals, responsible for mood, reward, and psychiatric states.

Yet, they govern the vast majority of our digestive functions.

The gut is, functionally, a second brain, wired with the exact same transmitters.

Which means the artificial wall we build between psychiatric drugs and GI drugs doesn't actually exist in the body.

The next time you're giving a psychiatric drug, an antidepressant or an antipsychotic, ask yourself,

what is this going to do to my patient's digestion?

Everything is connected.

You've got this.

Good luck on your exam, and a warm thank you for studying with the Last Minute Lecture Team.